#USA #Woodbury #Kindeva #David Stevens #Milton Boyer

Kindeva's Leadership Shift to Drive Innovation

Kindeva, a leading contract development and manufacturing organization in the drug delivery space, has unveiled a strategic transition in its leadership. As of January 1, 2026, David Stevens, previously the President of the company, will step into the role of CEO. With a noteworthy history of driving growth and operational excellence, Stevens is poised to steer Kindeva through its next phase of expansion, focusing on parenteral and inhaled drug delivery systems.

This leadership change comes as Milton Boyer, the outgoing CEO, has decided to step back but will retain a significant role as an independent member of Kindeva's Board of Directors. Boyer's contributions have been instrumental to Kindeva's trajectory, and his guidance will continue to influence the company as it navigates future challenges.

In a statement about his new role, Stevens expressed, "I am honored to succeed Milton at Kindeva and am eager to build upon the solid groundwork he laid. The unique culture of innovation and the commitment of our talented employees provide a bright outlook for our future." He emphasized the goal of enhancing partnership with customers to boost patient outcomes through advanced drug delivery solutions.

Kindeva's growth strategy includes expanding its manufacturing capacity and continued investment in enhancing service quality. The company aims to leverage its state-of-the-art facilities and innovative technology to maintain a competitive edge in the healthcare sector. Stevens also highlighted the importance of fostering collaboration within the organization to achieve ambitious industry goals.

George Aitken-Davies, co-founder and Managing Director at Altaris—which is an investment firm supportive of Kindeva—commented on the transition, stating that the changes come in light of a well-structured succession plan set in motion in October 2025. He noted that under Stevens’ leadership, Kindeva is well-positioned to achieve its strategic goals more effectively.

Kindeva's reputation is built upon a foundation of delivering quality development and manufacturing services. They are equipped with a global network of ten manufacturing and R&D sites which ensure they meet stringent compliance standards and are advancing toward sustainable solutions. This includes innovations like next-generation inhalation propellant technology.

The company’s mission, as summed up in their slogan, "We Manufacture More Tomorrows™ for patients worldwide," is a testament to their commitment to enhancing healthcare through superior drug delivery systems. They strive not only to meet current demands but also to pave the way for future advancements in patient treatment modalities.

Seamless transitions such as this one are vital for organizations like Kindeva, particularly in an industry as dynamic and essential as healthcare. As David Stevens takes on his new responsibilities, stakeholders, employees, and partners will be watching closely to see how his leadership will navigate the challenges ahead and drive the company forward into a promising future of growth and innovation.

About Kindeva

Kindeva is committed to improving the drug delivery landscape worldwide, providing a range of sophisticated services aimed at enhancing patient care through advanced technologies and manufacturing practices. To learn more about their initiatives and innovations, visit their website at www.kindevadd.com.

About Altaris

Altaris invests exclusively in developing and supporting companies within the healthcare sector, fostering growth that benefits the industry while generating returns for investors. Their expertise since 2003 underlines their capability in strategic healthcare investments. You can find more information at www.altariscap.com.